Francesco Giganti1, Martina Pecoraro2, Davide Fierro2, Riccardo Campa2, Francesco Del Giudice3, Shonit Punwani4, Alex Kirkham5, Clare Allen5, Mark Emberton6, Carlo Catalano2, Caroline M Moore6, Valeria Panebianco2. 1. Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK; Division of Surgery & Interventional Science, University College London, London, UK; Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy. Electronic address: f.giganti@ucl.ac.uk. 2. Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy. 3. Department of Urology, Sapienza University of Rome, Rome, Italy. 4. Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK; Centre for Medical Imaging, University College London, London, UK. 5. Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK. 6. Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.
Abstract
PURPOSE: The PRECISE score estimates the likelihood of radiological progression in patients on active surveillance (AS) for prostate cancer (PCa) with serial multiparametric magnetic resonance imaging (mpMRI). A PRECISE score of 1 or 2 denotes radiological regression, PRECISE 3 indicates stability and PRECISE 4 or 5 implies progression. We evaluated the inter-reader reproducibility of different apparent diffusion coefficient (ADC) calculations and their relationship to the PRECISE score. MATERIAL AND METHODS: Baseline and follow-up scans (on the same MR systems) of 30 patients with visible lesions from two different institutions (University College London and Sapienza University of Rome) were analysed by two radiologists (one from each site). The PRECISE score was initially assessed in consensus. At least six weeks later, to reduce the likelihood of being influenced by the consensus PRECISE reading, each radiologist independently calculated ADC for the following: lesion, non-cancerous tissue and urine in the bladder. Normalised ADC ratios were calculated with respect to normal prostatic tissue (npADC) and urine. Spearman's correlation (ρ), intraclass correlation coefficients (ICC), differences in ADC and ROC curves were computed. RESULTS: Interobserver reproducibility was very good (ρ > 0.8; ICC > 0.90). Lesion ADC (0.91 vs 0.73 × 10-3 mm2/s; p=0.025) and npADC ratio (0.68 vs 0.53; p=0.012) at follow-up mpMRI were different between patients with radiological regression or stability vs progression. Cut-offs of 0.77 × 10-3 mm2/s (lesion ADC) and 0.59 (npADC ratio) could differentiate the two groups (area under the curve: 0.74 and 0.77, respectively). CONCLUSION: The ADC, npADC ratio and the PRECISE score should be recorded for MRI-based AS.
PURPOSE: The PRECISE score estimates the likelihood of radiological progression in patients on active surveillance (AS) for prostate cancer (PCa) with serial multiparametric magnetic resonance imaging (mpMRI). A PRECISE score of 1 or 2 denotes radiological regression, PRECISE 3 indicates stability and PRECISE 4 or 5 implies progression. We evaluated the inter-reader reproducibility of different apparent diffusion coefficient (ADC) calculations and their relationship to the PRECISE score. MATERIAL AND METHODS: Baseline and follow-up scans (on the same MR systems) of 30 patients with visible lesions from two different institutions (University College London and Sapienza University of Rome) were analysed by two radiologists (one from each site). The PRECISE score was initially assessed in consensus. At least six weeks later, to reduce the likelihood of being influenced by the consensus PRECISE reading, each radiologist independently calculated ADC for the following: lesion, non-cancerous tissue and urine in the bladder. Normalised ADC ratios were calculated with respect to normal prostatic tissue (npADC) and urine. Spearman's correlation (ρ), intraclass correlation coefficients (ICC), differences in ADC and ROC curves were computed. RESULTS: Interobserver reproducibility was very good (ρ > 0.8; ICC > 0.90). Lesion ADC (0.91 vs 0.73 × 10-3 mm2/s; p=0.025) and npADC ratio (0.68 vs 0.53; p=0.012) at follow-up mpMRI were different between patients with radiological regression or stability vs progression. Cut-offs of 0.77 × 10-3 mm2/s (lesion ADC) and 0.59 (npADC ratio) could differentiate the two groups (area under the curve: 0.74 and 0.77, respectively). CONCLUSION: The ADC, npADC ratio and the PRECISE score should be recorded for MRI-based AS.
Authors: Luke P O'Connor; Alex Z Wang; Nitin K Yerram; Lori Long; Michael Ahdoot; Amir H Lebastchi; Sandeep Gurram; Johnathan Zeng; Stephanie A Harmon; Sherif Mehralivand; Maria J Merino; Howard L Parnes; Peter L Choyke; Joanna H Shih; Bradford J Wood; Baris Turkbey; Peter A Pinto Journal: Eur Urol Oncol Date: 2020-10-21
Authors: Francesco Giganti; Armando Stabile; Vasilis Stavrinides; Elizabeth Osinibi; Adam Retter; Clément Orczyk; Valeria Panebianco; Bruce J Trock; Alex Freeman; Aiman Haider; Shonit Punwani; Clare Allen; Alex Kirkham; Mark Emberton; Caroline M Moore Journal: Eur Radiol Date: 2020-09-30 Impact factor: 5.315